273 related articles for article (PubMed ID: 15632954)
21. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
22. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patients.
McQuarrie SA; Baum RP; Niesen A; Madiyalakan R; Korz W; Sykes TR; Sykes CJ; Hör G; McEwan AJ; Noujaim AA
Nucl Med Commun; 1997 Sep; 18(9):878-86. PubMed ID: 9352556
[TBL] [Abstract][Full Text] [Related]
24. Assessment of exposure after injection of
Mostafa MYA; Zakaly HMH; Zhukovsky M
Radiol Phys Technol; 2019 Mar; 12(1):96-104. PubMed ID: 30604358
[TBL] [Abstract][Full Text] [Related]
25. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
26. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso.
Cutler PD; Schwarz SW; Anderson CJ; Connett JM; Welch MJ; Philpott GW; Siegel BA
J Nucl Med; 1995 Dec; 36(12):2363-71. PubMed ID: 8523133
[TBL] [Abstract][Full Text] [Related]
27. Internal radiation dose assessment of radiopharmaceuticals prepared with cyclotron-produced
Meléndez-Alafort L; Ferro-Flores G; De Nardo L; Bello M; Paiusco M; Negri A; Zorz A; Uzunov N; Esposito J; Rosato A
Med Phys; 2019 Mar; 46(3):1437-1446. PubMed ID: 30661241
[TBL] [Abstract][Full Text] [Related]
28. Intraindividual comparison of 99mTc-labelled anti-SSEA-1 antigranulocyte antibody and 99mTc-HMPAO labelled white blood cells for the imaging of infection.
Gratz S; Behr T; Herrmann A; Dresing K; Tarditi L; Franceschini R; Rhodes B; Stürmer KM; Becker W
Eur J Nucl Med; 1998 Apr; 25(4):386-93. PubMed ID: 9553168
[TBL] [Abstract][Full Text] [Related]
29. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution and Dosimetry of Indigenously Produced
Adnan A; Deep K; Kameswaran M; Nikam D; Shanmukaih C; Dash A; Banerjee S; Basu S
J Nucl Med Technol; 2019 Dec; 47(4):292-299. PubMed ID: 30413603
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
Buchmann I; Kull T; Glatting G; Bunjes D; Hale G; Kotzerke J; Rattat D; Dohner H; Reske SN
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):667-73. PubMed ID: 12599012
[TBL] [Abstract][Full Text] [Related]
33. Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy.
Dou S; Smith M; Wang Y; Rusckowski M; Liu G
Cancer Biother Radiopharm; 2013 May; 28(4):335-42. PubMed ID: 23469942
[TBL] [Abstract][Full Text] [Related]
34. Biokinetics, radiopharmacokinetics and estimation of the absorbed dose in healthy organs due to Technetium-99m transported in the core and on the surface of reconstituted high-density lipoprotein nanoparticles.
Pérez-Velasco DL; Morales-Avila E; Ocampo-García B; Torres-García E; Izquierdo G; Jiménez-Mancilla N; Oros-Pantoja R; Díaz-Sánchez LE; Aranda-Lara L; Isaac-Olivé K
Nucl Med Biol; 2023; 122-123():108363. PubMed ID: 37419070
[TBL] [Abstract][Full Text] [Related]
35. Primary radiation dosimetry of a novel PET radiopharmaceutical
Cheki M; Gali H
Hell J Nucl Med; 2017; 20(3):241-246. PubMed ID: 29177263
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo comparison of binding of 99m-Tc-labeled anti-CEA MAb F33-104 with 99m-Tc-labeled anti-CEA MAb BW431/26.
Watanabe N; Oriuchi N; Sugiyama S; Kuroki M; Matsuoka Y; Tanada S; Murata H; Inoue T; Sasaki Y
Nuklearmedizin; 1999; 38(4):115-9. PubMed ID: 10392376
[TBL] [Abstract][Full Text] [Related]
37. Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line.
Tejuca M; Díaz I; Figueredo R; Roque L; Pazos F; Martínez D; Iznaga-Escobar N; Pérez R; Alvarez C; Lanio ME
Int Immunopharmacol; 2004 Jun; 4(6):731-44. PubMed ID: 15135315
[TBL] [Abstract][Full Text] [Related]
38. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
39. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
